The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with HCC.

The systemic therapy landscape of hepatocellular cancer (HCC) has evolved in recent years as data has become available about the efficacy of immunotherapy in this disease. It can be challenging for health care professionals to keep up with the latest data.

Hepatocellular carcinoma (HCC) is associated with poor prognosis, and many patients are diagnosed at an advanced stage. It is essential that all patients be evaluated by a multidisciplinary team prior to treatment initiation.

The goal of this program is to improve the knowledge and competence of learners to individualize the therapeutic management of patients with hepatocellular carcinoma (HCC).

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

The goal of this program is to improve the knowledge and competence of learners to individualize the therapeutic management of patients with hepatobiliary cancers.
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with hepatocellular carcinoma.

The goal of this activity is to improve participants’ competence in applying the latest treatment approaches and interdisciplinary collaborative strategies towards optimal care of patients with hepatocellular carcinoma.

Incidence and mortality rates for most cancers are declining; however, the incidence and mortality rates for liver cancer are increasing. A thorough understanding of the different approaches to treatment can help clinicians identify the optimal treatment strategy. Keeping clinicians abreast of new developments in the field can better inform clinical decision-making.
While relatively rare, biliary tract cancers have a poor prognosis. Recently, molecular profiling has become increasingly useful as some new targeted therapies received FDA approval. It is important for clinicians to keep abreast of new and upcoming therapies in order to develop an optimal treatment strategy.
While relatively rare, biliary tract cancers have a poor prognosis. Recently, molecular profiling has become increasingly useful as some new targeted therapies received FDA approval. It is important for clinicians to keep abreast of new and upcoming therapies in order to develop an optimal treatment strategy.

Pages

Subscribe to RSS - Hepatocellular Carcinoma